Thromboxane A2 and Osteoarthritis
- Conditions
- Osteoarthritis
- Interventions
- Other: biological samples
- Registration Number
- NCT05593640
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Brief Summary
TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i) to analyse the role of TXA2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue TXA2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of TXA2 with the development of osteoarthritis in a small human cohort. The proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat OA and associated metabolic disorders.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 20
- presence of knee osteoarthritis with effusion, , no inflammatory disease
- anticoagulant treatment
- inflammatory disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ThroboxaneOA biological samples Patient with osteoarthritis and knee effusion
- Primary Outcome Measures
Name Time Method to look for correlation between the rate of throboxane and the grade of osteoarthritis 6 months kellgren and lawrence classification
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU de NICE
🇫🇷NICE Cedex 1, France